Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21238192 | 0.79 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL16831456 | 0.79 | MEN1 (0.31) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL374245 | 0.78 | MEN1 (0.38) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL29999154 | 0.77 | MEN1 (0.31) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL30413564 | 0.76 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL29838273 | 0.76 | MEN1 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14358586 | 0.75 | MEN1 (0.36) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL14358168 | 0.75 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL17668676 | 0.75 | MEN1 (0.33) | MEN1KMT2AKDM4CL3MBTL1 | |
| SCHEMBL24412331 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | MEN1 4446/4885KMT2A 2988/4885KDM4C 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.